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Introduction
Frontal alpha asymmetry (FAA) is a proposed prognostic biomarker in major depressive disorder (MDD), conventionally acquired with electroencephalography (EEG). Although small studies attributed trait-like properties to FAA, a larger sample is needed to reliably asses this characteristic. Furthermore, to use FAA to predict treatment response, determining its stability, including the potential dependency on depressive state or medication, is essential.
Methods
In the international Study to Predict Optimized Treatment in Depression (iSPOT-D), a multicenter, randomized, prospective open-label trial, 1008 MDD participants were randomized to treatment with escitalopram, sertraline or venlafaxine-extended release. Treatment response was established eight weeks after treatment initiation and resting state EEG was measured both at baseline and after eight weeks (n=453).
Results
FAA did not change significantly after eight weeks of treatment (n=453, p=.234), nor did we find associations with age, sex, depression severity, or change in depression severity. After randomizing females to escitalopram or sertraline, for whom treatment response could be predicted in an earlier study, FAA after eight weeks resulted in equivalent response prediction as baseline FAA (one tailed p=.028).
Conclusion
We demonstrate that FAA is a stable trait, robust to time, state and pharmacological status.
This confirms FAA stability. Furthermore, as prediction of treatment response is irrespective of moment of measurement and use of medication, FAA can be used as a state-invariant prognostic biomarker with promise to optimize MDD treatments.
INTRODUCTION
Frontal alpha asymmetry (FAA) is a proposed biomarker conventionally acquired with electroencephalography (EEG). FAA has been studied for over three decades in major depressive disorder (MDD), anxiety, and other psychiatric diseases. Several studies stated, in a traditional framework of FAA, that it reflects the approach-withdrawal motivation system, i.e. the diathesis model (Davidson 1984; Harmon-Jones & Allen, 1997; Henriques & Davidson, 1991; Kelley, Hortensius, Schutter, & Harmon-Jones, 2017) . Left-sided FAA (i.e. more right-sided frontal cortical activation than left-sided) was correlated more to withdrawal behavior than to approach, which was in turn associated with a vulnerability to developing MDD. However, our meta-analysis showed that FAA cannot be used as a generic diagnostic biomarker in MDD and does not reliably differentiate MDD from non-MDD patients (van der Vinne, Vollebregt, van Putten, & Arns, 2017) , providing evidence against the diathesis model. Only a small subgroup of severely depressed females over 53 years of age showed more right-sided alpha activity and severely depressed males over 53 years of age more left-sided alpha than control peers.
When regarding FAA as a prognostic rather than diagnostic biomarker, alpha asymmetry may be more promising. Bruder and colleagues (2008) found SSRIs (selective serotonin reuptake inhibitors) treatment responders to have more right-sided alpha asymmetry while non-responders showed opposite asymmetry, primarily over the occipital region. This was confirmed in the large international Study for Predicting Optimized Treatment -Depression sample, where specifically female SSRI responders had more right-sided FAA, and nonresponders the opposite (iSPOT-D, Arns et al., 2016) . To further assess properties of FAA as a prognostic biomarker, knowledge on its reliability, stability, and sensitivity to other factors, such as medication or severity of depression, needs to be established.
A predominant view in affective neuroscience is that FAA in depressed patients consists of mostly trait-like features, not changing over time with state and independent of interventions, although some studies have suggested otherwise: both longitudinal and crosssectional designs have been used to test FAA stability (see Table 1 for a summary, and appendix table A for a detailed overview of studies). With an exception of Debener et al. (2000) , most studies report FAA to be stable with minor or no changes between baseline and assessment later, both in patients and healthy controls (Allen, Urry, Hitt, & Coan, 2004; Bruder et al., 2008; Davidson et al., 2003; Deldin & Chiu, 2005; Gollan et al., 2014; Keune, Bostanov, Hautzinger, & Kotchoubey, 2011; Spronk, Arns, Bootsma, van Ruth, & Fitzgerald, 2008; Sutton & Davidson, 1997; Tomarken, Davidson, Wheeler, & Kinney, 1992) .
Cross-sectionally, several studies showed that FAA is independent of depression severity, both between patients (Allen et al., 2004; Arns et al., 2016; Feldmann et al., 2018; Gollan et al., 2014; Nusslock et al., 2018; van der Vinne et al., 2017; Vuga et al., 2006) and within patients, including remission (Carvalho et al., 2011) . This contrasts the findings by Grünewald et al. (2018) and Keune et al. (2011) , where a higher level of depression complaints correlated with more left-sided FAA (albeit only in the control group of Grünewald et al.) . In other cross-sectional studies on FAA stability between depressed patients and patients remitted from depression, no differences were found (Carvalho et al., 2011; Feldmann et al., 2018; Gotlib, Ranganath, & Rosenfeld, 1998) .
Despite some inconclusive results, the majority of findings indicate that FAA is predominantly a trait, only partially or not affected by changes in depressive state. Our meta-analysis on FAA as a diagnostic marker of depression (van der Vinne et al., 2017) demonstrated that bias is strongly reduced from 300 cases onwards. Studies investigating FAA stability until now always studied smaller samples (n  85). This may explain part of the conflicting results on FAA in these studies.
This has motivated our current work that aims to replicate longitudinal results on the temporal stability of FAA by using data from the iSPOT-D dataset (baseline n=1008, week-8 n=453). The primary hypothesis was that FAA is reliable, and remains stable over time, with limited changes as a result of antidepressant treatment, time and state change. We therefore assessed FAA after eight weeks of antidepressant drugs and consequential state changes in mood. As age, sex, and depression severity have had a significant influence on FAA-related outcomes in iSPOT-D and other studies (e.g. Arns et al., 2016; Bruder et al., 2001; Stewart, Bismark, Towers, Coan, & Allen, 2010; van der Vinne et al., 2017) , we extended analyses by investigating possible mediation of FAA by these variables. We specifically studied MDD patients versus healthy controls differentiating subgroups identified in our previous meta-analysis, i.e. severely depressed patients over 53 years old (van der Vinne et al., 2017) . As in earlier iSPOT-D reports on FAA anxiety was not found to be of influence, we did not add this variable to our analyses. For clinical use of FAA as a biomarker for treatment response, it is relevant to assess stability and robustness to medication. Stability is particularly an advantage when patients are already on an AD preceding baseline (that often have long half-life times requiring wash-out periods of weeks) and FAA remains unaffected. We therefore also assess outcome prediction with FAA recorded after eight weeks treatment. In our previous report (Arns et al., 2016) , at baseline, right-sided FAA in females was associated with favorable outcome to the SSRIs escitalopram and sertraline, whereas left-sided FAA was not. If FAA is prognostic for AD treatment outcome in specific subsamples, and FAA is indeed a stable trait, FAA after 8 weeks on an AD should still be able to predict treatment outcome for females in agreement with our previous study (Arns et al., 2016) . We hypothesized that analysis of week-8 medicated EEG data would result in the same treatment prediction results as baseline unmedicated data did.
MATERIALS AND METHODS

Design
This is an international multi-center, randomized, prospective open-label trial (Phase-IV clinical trial) in which MDD patients were randomized to escitalopram, sertraline, or venlafaxine-XR treatment in a 1:1:1 ratio. The study protocol details, including a power calculation, have been published by Williams et al. (2011) . This design was deliberately chosen to mimic real-world practice with the aim of optimizing the translatability to real world settings.
MDD patients and treatment
We Grannemann, & Trivedi, 2017) . Comorbid anxiety disorders were allowed (present in 6.2%
[specific phobia] to 10.5% [social phobia] of patients). All patients were either medicationnaive or, if previously prescribed an antidepressant medication, had undergone a washout period of at least five half-lives before the baseline visit clinical and EEG assessments. After the baseline visit, patients were randomized to one of three antidepressant medication treatments. After eight weeks of treatment, patients were tested again using the HRSD 17 , the VQIDS-SR 5 and an EEG assessment (figure 1). This study was approved by the institutional review boards at all of the participating sites and this trial was registered with ClinicalTrials.gov. Registration number: NCT00693849; URL:
http://clinicaltrials.gov/ct2/show/NCT00693849. 2.3. Pre-treatment assessments EEG recordings were performed using a standardized methodology and platform (Brain Resource Ltd., Australia). Details of this procedure (Arns, Gunkelman, Breteler, & Spronk, 2008; Williams et al., 2011) and of its reliability and across-site consistency have been published elsewhere (Paul et al., 2007; Williams et al., 2005) . In summary, subjects were seated in a sound and light attenuated room that was controlled at an ambient temperature of 22 °C. EEG data were acquired from 26 channels: Fp1, Fp2, F7, F3, Fz, F4, F8, FC3, FCz, FC4, T3, C3, Cz, C4, T4, CP3, CPz, CP4, T5, P3, Pz, P4, T6, O1, Oz and O2 (Quik-cap; NuAmps; 10-20 electrode international system). EEG was assessed for two minutes with eyes open (EO) (with the subject asked to fixate on a red dot on the screen) and two minutes with eyes closed (EC). The subject was instructed to remain relaxed for the duration of the recording.
The operator did not intervene when drowsiness patterns were observed in the EEG. Data were referenced to averaged mastoids with a ground at AFz. Horizontal eye movements were recorded with electrodes placed 1.5 cm lateral to the outer canthus of each eye.
Vertical eye movements were recorded with electrodes placed 3 mm above the middle of the left eyebrow and 1.5 cm below the middle of the left bottom eyelid. Skin resistance was <5 K Ohms for all electrodes. The sampling rate of all channels was 500 Hz. A low pass filter with an attenuation of 40 dB per decade above 100 Hz was employed prior to digitization.
EEG analysis
A detailed overview of the data-analysis can be found in Arns et al. (2016) . In summary, data were 1) filtered (0.3-100 Hz and notch); 2) EOG-corrected using a regression-based technique similar to that used by Gratton, Coles, and Donchin (1983) , segmented in 4second epochs (50% overlapping), and an automatic de-artifacting method was applied. This EEG processing pipeline was also validated against an independent manual-processing pipeline (Arns et al., 2016) . For further analysis, an average reference was applied, data were filtered (alpha power (µV 2 ): 8-13 Hz) and FAA was calculated between F3 and F4 as (F4 -F3)/(F4 + F3).
Statistics
Normal distribution was inspected, and appropriate transformations performed in case of non-normality. Non-log transformed alpha power was used to calculate FAA. Remission was defined as a score 7 on the HRSD 17 eight weeks after starting treatment (current endpoint), and response was defined as a 50% decrease in HRSD 17 score from baseline to eight weeks.
To control for antidepressant side-effects, we employed the VQIDS-SR 5 , developed specifically to focus on the core symptoms of depression. This enabled us to measure true depression severity, ruling out antidepressant side-effects such as physical complaints. We repeated ANOVAs from paragraph 3.2 and 3.3 and replaced all HRSD 17 variables with VQIDS-SR 5 equivalents. Results are reported in appendix D.
Differences in age, sex, education, and depression severity at baseline were tested using one-way ANOVA or non-parametric tests, depending on its distribution. We only included patients who returned for their week-8 visit while on their assigned medication, having followed this treatment for a minimum of 6 weeks ('per-protocol' grouping, also see the Consort diagram in figure 1 ).
FAA reliability analysis was performed by calculating Intraclass Correlations (ICCs) across
baseline and week-8 measurements. A full-factorial Repeated Measures ANOVA was conducted with the within-subject factor FAA Change Eyes Closed (FAA at baseline and after eight weeks) and between-subject factor Treatment arm (comparing drug effects of respectively escitalopram, sertraline, and venlafaxine). Given the large sample size we set the significance level for main effects found for FAA Change in the main analyses at p≤.01, for interaction effects this remained at a conventional level of p≤.05. When significant interactions were found prompting subgroup analyses, again a level of p≤.05 was used. . We tested effects one-tailed (halved p-values were reported) because we specifically expected more right-sided FAA in SSRI responders than in non-responders, implying that a result in the unexpected direction would lead to the same conclusion as finding no differences at all (Ruxton & Neuhäuser, 2010) . In appendix B, we explain why we compare the smaller sample containing only patients who were present for the assessment after 8 weeks, to the larger sample with all baseline patients from the previous study.
RESULTS
Of the 1008 MDD patients enrolled, the final MDD sample for the FAA Change analyses consisted of 453 MDD patients. The remaining 555 patients were left out of the study: they either never started treatment, had less than 6 weeks of medication, or had no week-8 assessment (or it was of insufficient quality) (see figure 1 ). 
Extended Repeated Measures model and correlations
Focusing on variables known to have an influence on FAA, specifically in the subgroup we thought to be prone to changes in FAA (severely depressed females and males over 53 years old), we did not find significant changes, although subsample sizes were small. Furthermore, in these subgroups the FAA Change score was not significantly correlated to the change score in HRSD 17 (see appendix Cohen's d comparing FAA change scores of female SSRI responders and non-responders was .304. When using the direction of week-8 FAA alone to prescribe an SSRI or SNRI would have improved the overall remission rate from 47% to 56-58% for an SSRI. 
DISCUSSION
We investigated the stability of FAA in MDD patients during antidepressant treatment. We hypothesized that FAA is a robust metric, insensitive to time, antidepressant drug treatment and state changes. FAA did not change significantly after eight weeks of escitalopram, sertraline, or venlafaxine treatment, despite a relatively low reliability of the FAA measurements. Additional Bayesian testing revealed that a stable FAA is more likely than a change in FAA over time after antidepressant treatment. Furthermore, post-hoc tests with variables known to have influence on FAA (in earlier iSPOT-D studies), revealed no differential temporal changes in FAA in depressed patients differing on age, sex, depression severity, or change in depression severity. Focusing on core depression symptoms only (as measured by the VQIDS-SR 5 , see appendix D), we found similar results.
To further confirm FAA temporal stability, we hypothesized that predicting treatment outcome in females taking SSRIs would lead to similar outcome when using week-8 FAA instead of the previously studied baseline FAA (Arns et al., 2016) . This re-analysis indeed confirmed an overall response in the SSRI group with right-sided FAA, and a non-response with left-sided FAA. Although the effect size was less pronounced with week-8 data, week-8 FAA yielded the same conclusions as the baseline measurements, with a Cohen's d of .547 in the previous analyses vs. our current .304. Furthermore, we yielded the same improvement in remission rates when week-8 FAA had been used for 'prescribing' medication: previous SSRI remission rates improved from 46% to 53-60% using baseline FAA, the current from 47% to 56-58% using week-8 FAA. This extends the use of FAA as a prognostic biomarker, as response prediction was neither modified by moment of assessment, nor by AD treatment.
The low reliability was unexpected, and implies that FAA following treatment was not as stable as in previous studies.
In several studies, FAA was found to be relatively reliable and consistent, based on ICCs and Cronbach's alpha (Allen et al., 2004; Debener et al., 2000; Keune et al., 2011; Sutton & Davidson, 1997; Towers & Allen, 2009 ). Especially Towers and
Allen (2009) To our knowledge, this is the first study to assess the temporal stability of FAA in a large sample. This supports previous studies showing that FAA mainly depends on a considerable number of trait-like features, insensitive to antidepressant treatment, age, sex or depression severity (Allen, Urry, Hitt, & Coan, 2004; Arns et al., 2016; Bruder et al., 2008; Carvalho et al., 2011; Deldin & Chiu, 2005; Feldmann et al., 2018; Gollan et al., 2014; Keune, Bostanov, Hautzinger, & Kotchoubey, 2011; Nusslock et al., 2018; Spronk, Arns, Bootsma, van Ruth, & Fitzgerald, 2008; Sutton & Davidson, 1997; Tomarken, Davidson, Wheeler, & Kinney, 1992;  van der Vinne, Vollebregt, van Putten, & Arns, 2017; Vuga et al., 2006) . Similarly, Segrave and colleagues (2011) showed no evidence for antidepressant elicited changes in FAA when comparing a small group of depressed patients on ADs with unmedicated patients. In other small cohorts, FAA was not modified by the use of antidepressive medication either (Bruder et al., 2008; Vuga et al., 2006) , in agreement with our observations.
In the prevailing approach-withdrawal motivation system hypothesis, it is assumed that FAA is associated with lifetime MDD (having had at least one depressive episode in one's life),
and not specifically current MDD. This is an important distinction, and our results initially support this theory. The motivation system hypothesis states that FAA is not expected to change as a result of changes in MDD status, and ultimately not with MDD remission.
However, with establishing FAA (in)stability, our study would neither provide evidence for, nor against the theory. That is, if we would have found the opposite result (a change in FAA), this could have been explained as well, by the related capability model (Coan, Allen, & McKnight, 2006) . This model states that resting state FAA is more prone to fluctuations than FAA measured after inducing positive or negative mood. Because we measured resting state FAA, either outcome could be explained within the approach-withdrawal motivation system, given the capability model. Therefore, it is difficult to unambiguously place our results in the existing theories. Note that our earlier findings were less compatible with the motivation system: Firstly, in the approach-withdrawal motivation system, left-sided FAA is theorized to be more associated with withdrawal behavior and depression. But brain asymmetry was found not to be different in these groups as measured both through EEG FAA (van der Vinne et al., 2017) , and through fMRI in a recent large ENIGMA consortium study (de Kovel et al., 2019) . Secondly, prognostic results for females in the FAA iSPOT-D study (Arns et al., 2016) revealed heterogeneity in MDD patients, not consistent with assuming a homogenic FAA related vulnerability for MDD. In sum, the current study was not designed to directly investigate the approach-withdrawal motivation theory, and cannot provide support in favor of or against the theory.
We show that FAA is a robust metric, suitable for sex specific treatment prediction under challenging circumstances, such as state, time, the use of common antidepressive agents and drug changes. This suggests reliable implementation in clinical practice as a prognostic biomarker in both medicated and unmedicated patients.
CONCLUSIONS
In an adequately powered sample, we demonstrate that 1) neither antidepressant medication, 2) nor MDD state and severity, have systematic effects on FAA. This confirms FAA stability. Furthermore, as prognosis of treatment response is irrespective of the moment of measurement, FAA may serve as a robust biomarker to optimize MDD treatments. Females SSRI: Response p = .001 p = .001 p = .028
Females venlafaxine: Response p = .070 p = .011 p = .821 *Halved p-values due to one-tailed analysis Males FAA Change 0.029 (1, 194) .864
FAA Change * Treatment arm 0.282 (2, 194) .755
FAA Change * Age 0.024 (1, 194) .878
FAA Change * Depression severity 0.022 (1, 194) .881
FAA Change * Treatment arm * Age 0.292 (2, 194) .747
FAA Change * Treatment arm * Depression severity 0.471 (2, 194) .625
FAA Change * Age * Depression severity 0.052 (1, 194) .820
FAA Change * Treatment arm * Age * Depression severity 0.352 (2, 194) .704
D. VQIDS-SR 5
To control for AD side effects, we repeated analyses from paragraph 3.2 and 3.3 and replaced all HRSD 17 variables with VQIDS-SR 5 equivalents. Correlational analyses showed that FAA Change was neither significantly correlated to the change score in VQIDS-SR 5 (r = 0.059, p = .225), nor to the percentage change in VQIDS-SR 5 (r = 0.060, p = .219).
Focusing on variables known to have an influence on FAA, specifically in the subgroup we thought to be prone to changes in FAA (severely depressed females and males over 53 years old), we did not find the FAA Change score to be significantly correlated to the change score in VQIDS-SR 5 , although subsample sizes were small. Extending the Repeated Measures model from paragraph 3.2 showed that VQIDS-SR 5 baseline severity and age are not significantly contributing to FAA Change, both in males and females (see table D for all statistics). 
